This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Temozolomide (TMZ) is considered to be standard chemotherapy for the treatment of glioblastoma, but may cause lymphocytopenia thus potentiating the risk for opportunistic infections. Although one might anticipate that recurrent CMV infection may be precipitated by temozolomide immunosuppression, few cases of TMZ-induced cytomegalovirus (CMV) recurrent infection have been reported. Herein, we report a patient with malignant glioma who developed CMV pneumonia following TMZ therapy. The patient developed significant recurrent CMV infection with pneumonitis diagnosed by PCR (DNA analysis). Antiviral treatment with intravenous ganciclovir was administered. For patients with prior CMV exposure, it would be prudent to monitor CMV viral loads periodically to avoid recurrent CMV infection after exposure to TMZ and corticosteroid chemotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.